Journal article
The effect of emicizumab prophylaxis on long‐term, self‐reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies
Abstract
INTRODUCTION: Severe haemophilia A (HA) has a major impact on health-related quality of life (HRQoL).
AIM: Assess the impact of emicizumab on HRQoL in persons with severe HA (PwHA) without factor VIII (FVIII) inhibitors in the phase 3 HAVEN 3 and 4 studies.
Authors
Skinner MW; Négrier C; Paz‐Priel I; Chebon S; Jiménez‐Yuste V; Callaghan MU; Lehle M; Niggli M; Mahlangu J; Shapiro A
Journal
Haemophilia, Vol. 27, No. 5, pp. 854–865
Publisher
Wiley
Publication Date
September 2021
DOI
10.1111/hae.14363
ISSN
1351-8216